SCAI Bifurcation Club Formed to Promote Worldwide Excellence in Coronary Artery Bifurcation Interventions
September 28, 2020—The Society for Cardiovascular Angiography and Interventions (SCAI) announced the formation of the SCAI Bifurcation Club, an initiative dedicated to promoting excellence in coronary artery bifurcation interventions worldwide through innovation, research, technologic advances, education, point-of-care tools, and production of consensus documents and guidelines.
InnovHeart Announces First-In-Human Implantation of Saturn TMVR System and 30-Day Results
September 24, 2020–InnovHeart s.r.l. announced the successful first-in-human implantation of the company’s Saturn transcatheter mitral valve replacement (TMVR) system, which demonstrated excellent results in the first patient at 30-day follow-up.
Robert W. Gore, Chairman Emeritus of W. L. Gore & Associates and Inventor of Gore-Tex, Dies at 83
September 21, 2020—Robert W. “Bob” Gore, chairman emeritus of the board of directors of W. L. Gore & Associates, the global material science company, passed away on September 17 at the age of 83, the company announced.
VitalConnect Begins TELESTAR-TAVR Study of Remote Patient Monitoring System
September 16, 2020—VitalConnect, Inc. announced that it has begun the TELESTAR-TAVR clinical study that is evaluating the company’s VistaSolution Live technology to monitor patients after undergoing transcatheter aortic valve replacement (TAVR).
FDA Grants Fast Track Designation for Jardiance to Prevent Heart Failure in Patients After Acute MI
September 15, 2020—Boehringer Ingelheim and Eli Lilly and Company jointly announced that the FDA has granted Fast Track designation for the development of Jardiance (empagliflozin, an SGLT2 inhibitor) to prevent hospitalization for heart failure and reduce the risk of mortality in patients, with and without diabetes, who have had an acute myocardial infarction (MI).
Study Shows Relation of LDL Cholesterol Levels and PCI Outcomes
September 14, 2020—The American College of Cardiology (ACC) reported new findings indicating that levels of low-density lipoprotein cholesterol (LDL-C) after coronary revascularization with percutaneous coronary intervention (PCI) were strongly associated with the subsequent incidence of major adverse cardiovascular events (MACE).